NVAX News & Events

Novavax (NVAX) has entered into a license agreement with Pfizer (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms of the agreement, Pfizer will obtain a non-exclusive license for Matrix-M for use with Pfizer's products in up to two disease areas. Under the terms of the license agreement: Novavax will receive an upfront payment of $30M and the potential to receive up to $500M in development and sales milestones. In addition to milestone payments, Novavax is eligible to receive tiered high mid-single digit percentage royalty payments on sales of any product by Pfizer that includes Matrix-M. Pfizer will be solely responsible for the development and commercialization of its products utilizing Matrix-M. Novavax will be responsible for the supply of Matrix-M.

Advisers to Health Secretary Robert F. Kennedy Jr. are considering major revisions to the childhood vaccination schedule, including delaying or potentially removing the routine hepatitis B shot given at birth, The New York Times' Apoorva Mandavilli reports. Although not legally binding, their decisions could significantly influence insurance coverage and public health guidelines, with members also expected to debate vaccine ingredients and the use of combination shots, Mandavilli writes. Publicly traded companies that could be impacted include Moderna (MRNA), Pfizer (PFE), BioNTech (BNTX), Novavax (NVAX), AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY), and Sanofi (SNY).